To the full analysis
Silence Therapeutics stock: growth
SLNSilence Therapeutics reported $559K in revenue for fiscal 2025, down 98.7% on the prior year, down 70.4% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
−6.4%
per year from 2006 to 2025, per share −20.4%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | −36.7% | no data | −6.4% |
| Revenue per share | −29.3% | no data | −20.4% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $1.95M | −$3.83M | −$4.16M |
| 2007 | $4.05M | −$5.11M | −$4.36M |
| 2008 | $2.21M | −$7.44M | −$7.25M |
| 2009 | $1.72M | −$7.47M | −$4.87M |
| 2010 | $2.37M | −$8.8M | −$10.84M |
| 2011 | $720.13K | −$5.74M | −$5.39M |
| 2012 | $163K | −$26.28M | −$5.08M |
| 2013 | $117K | −$9M | −$6.89M |
| 2014 | $15K | −$11.09M | −$9.8M |
| 2015 | $0 | −$6.65M | −$9.11M |
| 2016 | $770K | −$8.44M | −$10.6M |
| 2017 | $16K | −$1.62M | −$9.77M |
| 2018 | $0 | −$18.41M | −$16.95M |
| 2019 | $244K | −$19.58M | $1.72M |
| 2020 | $5.48M | −$32.55M | −$11.29M |
| 2021 | $12.42M | −$39.41M | $7.39M |
| 2022 | $17.65M | −$41.03M | −$57.59M |
| 2023 | $25.38M | −$43.27M | −$39.4M |
| 2024 | $43.26M | −$45.31M | −$54.22M |
| 2025 | $559K | −$88.61M | −$62.33M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Sep 2021)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.